thymosin alpha 1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-08. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Aila Inkeri Keto AO (born 14 March 1943) is an Australian environmentalist. She is the founder and President of the Rainforest Conservation Society in Queensland, Australia, now known as the Australian Rainforest Conservation Society. In 2005, Keto was a recipient of the Queensland Greats Awards. Born in Tully, Queensland, Australia, to parents of Finnish origin, Dr Keto originally studied biochemistry and worked at the University of Queensland. In 1992, Keto received the IUCN Fred M. Packard Award in recognition of "outstanding service to protected and conserved areas" and in 1994 she was awarded an Officer of the Order of Australia for “service to conservation, particularly through promoting the protection and management of the wet tropical rainforests of Queensland”. She was nominated as Queenslander of the Year in 2000 and in 2001 she was awarded a Centenary Medal, "for service as an expert on wet tropics and as a leading conservationist and academic". In 2005, Dr Keto was awarded the Volvo Environment Prize for her work which, led to the protection of more than 15,000 square kilometres (5,800 sq mi) of Queensland's rainforest. This is only one of a series of awards that have been given to her for her environmental and conservation work which has resulted in three successful nominations for world heritage status: Wet Tropics, Fraser Island and the Central Eastern Rainforest Reserves of Australia (now Gondwana Rainforests of Australia).
=== Main === Kathy Bates as Madeline "Matty" Matlock / Madeline Kingston, who claims to be a widowed lawyer, returning to the workforce following decades of retirement due to financial distress from her husband's gambling troubles, and having to raise her grandson following her daughter's death in a car accident. Matlock takes a job as an associate at the law firm Jacobson Moore, working with Olympia, a junior partner at the firm who becomes her boss. In fact, Kingston is wealthy and happily married, though indeed grieving the loss of her daughter who died from an opioid overdose and seeking retribution. She gave herself the alias of "Matlock" after the original television series. Skye P. Marshall as Olympia Lawrence, a junior partner at Jacobson Moore who becomes Matlock's boss. In the pilot episode, she is in the midst of divorcing Julian while aiming at a senior partner role with the support of her father-in-law. Olympia is reluctant to take Matty under her wing as she acknowledges that Matty is the threat to her promotion in the law firm due to her exceptional skills. Jason Ritter as Julian Markston, a senior partner at Jacobson Moore. In the pilot episode, he is in the midst of divorcing Olympia and engaged in a major settlement action involving a large pharmaceutical corporation. David Del Rio as Billy Martinez (seasons 1–2), a first-year associate at Jacobson Moore working with Olympia. Del Rio makes his last appearance in episode 7 of the second season following his dismissal from the series.
25% of patients treated with arsenic trioxide exhibited symptoms resembling leukocyte activation syndrome, characterized by high fever, shortness of breath, weight gain, pulmonary infiltrates with pleural or pericardial exudation, with or without leukocytosis. High doses of steroids (10 mg dexamethasone intravenously, 2–3 times per day) appear to alleviate these symptoms. 40% of patients treated with arsenic trioxide experienced at least one instance of prolonged QT interval, corrected to over 500 ms. QT interval prolongation can lead to ventricular arrhythmias, such as torsades de pointes. Prior to initiating arsenic trioxide treatment, an ECG should be performed, and blood levels of potassium, calcium, magnesium, and creatinine should be checked. Any abnormalities, particularly a prolonged QT interval on the ECG, should be corrected before starting arsenic trioxide. Any medications that may prolong the QT interval should be discontinued if possible. Patients receiving arsenic trioxide, particularly those at risk for torsades de pointes, should be closely monitored during treatment. If toxicity reaches level 3 (as per National Cancer Institute criteria), treatment should be modified or discontinued before the planned completion of therapy. Patients can resume treatment only after symptoms subside, starting with 50% of the prior daily dose. The dose can be increased to the previous level if no toxicity symptoms appear within 3 days. If toxicity reappears, treatment with arsenic trioxide cannot continue.
Phosphatidylinositol kinases phosphorylate phosphatidylinositol species, to create species such as phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2), phosphatidylinositol 3,4,5-trisphosphate (PIP3), and phosphatidylinositol 3-phosphate (PI3P). The kinases include phosphoinositide 3-kinase (PI3K), phosphatidylinositol-4-phosphate 3-kinase, and phosphatidylinositol-4,5-bisphosphate 3-kinase. The phosphorylation state of phosphatidylinositol plays a major role in cellular signalling, such as in the insulin signalling pathway, and also has roles in endocytosis, exocytosis and other trafficking events. Mutations in these kinases, such as PI3K, can lead to cancer or insulin resistance. The kinase enzymes increase the rate of the reactions by making the inositol hydroxyl group more nucleophilic, often using the side chain of an amino acid residue to act as a general base and deprotonate the hydroxyl, as seen in the mechanism below. Here, a reaction between adenosine triphosphate (ATP) and phosphatidylinositol is coordinated. The end result is a phosphatidylinositol-3-phosphate as well as adenosine diphosphate (ADP). The enzymes can also help to properly orient the ATP molecule, as well as the inositol group, to make the reaction proceed faster. Metal ions are often coordinated for this purpose.
Sources: en.wikipedia.org
Knowledge includes experiences of people in the organization, company reports, case histories, databases and other repositories In order for organizations to become agile, organizations, they need to focus on building knowledge bases and cultivating a well trained and motivated workforce. Such an organization is driven by knowledge and information available and possessed by the workforce. This epitomizes the notion that `knowledge is power'. "The ability to control the new product introduction process from the conceptualization and design stages through manufacturing to shipment and product support requires the exploitation of a knowledge-rich work force and sophisticated information technology in most industrial sectors"
It is believed that the tyrosine amino acid found along the amino acid sequence of alpha-sarcin allows for the specificity when alpha-sarcin binds to the rRNA. It is the alcohol group found on the tyrosine amino acid that allows for this binding. This was determined in tests that removed the alcohol group, replacing tyrosine with phenylalanine, and the binding affinity was greatly reduced. The region of the DNA that makes alpha-sarcin is highly conserved, along with the corresponding sequence on the targeted ribosome. The corresponding sequence on the targeted ribosome is a centered around a guanine nucleotide located on what is called the "bulged-G motif".
The localization of ADAM17 is speculated to be an important determinant of shedding activity. TNF-α processing has classically been understood to occur in the trans-Golgi network, and be closely connected to transport of soluble TNF-α to the cell surface. Shedding is also associated with clustering of ADAM17 with its substrate, membrane bound TNF, in lipid rafts. The overall process is called substrate presentation and regulated by cholesterol. Research also suggests that the majority of mature, endogenous ADAM17 may be localized to a perinuclear compartment, with only a small amount of TACE being present on the cell surface. The localization of mature ADAM17 to a perinuclear compartment, therefore, raises the possibility that ADAM17-mediated ectodomain shedding may also occur in the intracellular environment, in contrast with the conventional model. Functional ADAM17 has been documented to be ubiquitously expressed in the human colon, with increased activity in the colonic mucosa of patients with ulcerative colitis, a main form of inflammatory bowel disease. Other experiments have also suggested that expression of ADAM17 may be inhibited by ethanol.
The Oculus Rift announcement led to other VR developments. Sony Computer Entertainment developed the PlayStation VR system for the PlayStation 4, while Valve partnered with HTC to develop the HTC Vive; both of these units were released in 2016. Valve later developed their own headset without HTC, the Valve Index, which was released in 2019.
Psychiatric diagnoses take place in a wide variety of settings and are performed by many different health professionals. Therefore, the diagnostic procedure may vary greatly based upon these factors. Typically, though, a psychiatric diagnosis utilizes a differential diagnosis procedure where a mental status examination and physical examination is conducted, with pathological, psychopathological or psychosocial histories obtained, and sometimes neuroimages or other neurophysiological measurements are taken, or personality tests or cognitive tests administered. In some cases, a brain scan might be used to rule out other medical illnesses, but at this time relying on brain scans alone cannot accurately diagnose a mental illness or tell the risk of getting a mental illness in the future. Some clinicians are beginning to utilize genetics and automated speech assessment during the diagnostic process but on the whole these remain research topics.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.